CD274 and neoplasm: Combined therapy with anti-PD-L1 and BET bromodomain inhibitor i-BET762, which is currently in clinical trials, synergistically inhibited the suppressive function of M-MDSCs and enhanced tumor-infiltrating lymphocytes in a fibrotic-HCC mouse model [115].